Tumor redox heterogeneity-responsive prodrug nanocapsules for cancer chemotherapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 23740675.
- Also identified by DOI 10.1002/adma.201300929.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A prodrug forms nanocapsules responsive to tumor GSH/ROS heterogeneity releasing the parent drug SN38 via thiolysis in the presence of GSH (glutathione) or via enhanced hydrolysis due to ROS (reactive oxygen species)-oxidation of the linker, giving rise to high in vitro cytotoxicity and in vivo anticancer therapeutic activity. The nanocapsules are a suitable size for tumor targeting by means of the EPR effect and have a fixed SN38 loading content of 35 wt%, ideal for translational nanomedicine.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Camptothecin
- Nanocapsules
- Neoplasms
- Prodrugs